Types segmentation differentiates the technological families that generate the aerosol plume. The dominant metered‑dose inhaler (MDI) class, comprising pressurized‑canister devices, contributes roughly 40 % of unit shipments because of its long‑standing regulatory approval and extensive formulary presence. Dry‑powder inhalers (DPI) capture about 30 % of the market; they rely on patient‑driven inspiratory flow and are favored for high‑dose formulations due to their powder‑loading capacity. Nebulizers, representing about 20 % of the market, are essential for patients unable to coordinate inhalation, offering continuous aerosol generation for both hospital and home settings. Emerging soft‑mist inhalers (SMI), accounting for the remaining 10 %, employ mechanical actuation to produce a slow‑moving plume that enhances pulmonary deposition while reducing oropharyngeal exposure. Each type’s sub‑categories—such as breath‑actuated versus static‑dose MDIs, ultrasonic versus jet nebulizers, or capsule‑based versus multi‑dose DPIs—further refine the market taxonomy, influencing cost structures, device lifecycle, and adoption rates across the application spectrum. Consequently, manufacturers prioritize R&D investment in the higher‑share categories while monitoring regulatory trends that could shift the relative importance of emerging sub‑types.
